Justin Zelin is a Director and BTIG Biotechnology Analyst, specializing in cell therapy, targeted oncology, immunology and auto-immune disease therapeutics. Prior to BTIG, Mr. Zelin was a Biotech Equity Research Analyst at B. Riley Securities. Previously, he held biotech equity research associate roles at Canaccord Genuity and SVB Leerink. Earlier in his career, Mr. Zelin worked in both academic and industry labs including Agenus, Harvard University and Brigham and Women’s Hospital. He was also a member of Harvard University’s teaching staff for more than five years. Mr. Zelin earned a master’s degree in biotechnology and a bachelor’s degree in biology from Harvard University.
|Adicet Bio, Inc.||ACET|
|Legend Biotech Corp.||LEGN|
|Mustang Bio, Inc.||MBIO|
|Poseida Therapeutics, Inc.||PSTX|
|Surface Oncology, Inc.||SURF|
|CASI Pharmaceuticals, Inc.||CASI|